Many studies have shown that IL-6 plays a significant role in defining the immune/alloimmune response. New therapies targeting pro-inflammatory cytokines are now available for the treatment of rheumatoid arthritis. Blockade of IL-6, Th17 related and other cytokines may not only decrease the pro-inflammatory response, but more importantly may favor a regulatory T cell response and thus potentially influence long-term allograft survival.
Beth Israel Deaconess Medical Center, Harvard Medical School
You must be logged in and own this session in order to